Catapult Therapeutics receives FDA Clearance of Investigational New Drug (IND) Application for CAP-100, an innovative first-in-class humanized anti-CCR7 antibody
/PRNewswire/ -- Catapult Therapeutics, a biopharmaceutical company developing novel cancer treatments, today announced the U.S. Food and Drug Administration...
Source: prnewswire.com